HC Wainwright & Co. maintains Compass Pathways at Buy, keeps price target at $65
HC Wainwright & Co. reiterated a Buy rating for Compass Pathways (CMPS) with a $65 price target, implying a 654.9% upside from the Nov 6 close of $8.61.
How this was made
The 30-second read
Why it matters
The upgrade could attract short‑term buying, but the lack of concrete catalyst limits sustained price movement.
Market read
A rating upgrade for a micro‑cap biotech may spark brief interest but is unlikely to move broader markets.
What to watch
No new clinical data or regulatory milestones accompany the rating change.
Background
Compass Pathways is a psychedelic‑therapy company listed on Nasdaq (CMPS). Analyst coverage is sparse, making rating changes notable.
Ticker impact
HC Wainwright upgraded Compass Pathways to Buy and kept a $65 price target, implying a 654.9% upside from the recent close.
likely upward pressure as investors price in the large upside potential
The rating change is a fresh analyst opinion with a substantial target, but no new corporate event or earnings data.
Market effects
May lift sentiment in the biotech/psychedelic therapy sector.
Limited to investors focused on US-listed biotech stocks.
Minimal; primarily relevant to niche biotech investors.
Counterpoint
The target may be overly optimistic given the company's early-stage pipeline.
Key entities
- AnalystHC Wainwright & Co.
Equity research firm that issued the rating upgrade.
- CompanyCompass Pathways plc
Biotech firm developing psilocybin‑based therapies.
